Evidence map›Paper›PMID 41045325›Full record

Observational studyOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on bone mineral density.

Maarten J Beekman, Lara Terra, Anniek Stuursma, Bernadette A M Heemskerk-Gerritsen, Jeanine E Roeters van Lennep, Marc van Beurden, Lena C van Doorn, Joanne A de Hullu, Eleonora B L van Dorst, Constantijne H Mom and 22 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03835793 (Favourable and Unfavourable Health Effects of Risk-Reducing Salpingo-Oophorectomy in Women With a High Genetic Risk of Ovarian Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03835793 unknown statusnot on this map

Favourable and Unfavourable Health Effects of Risk-Reducing Salpingo-Oophorectomy in Women With a High Genetic Risk of Ovarian Cancer

TypeobservationalSponsorThe Netherlands Cancer InstituteRan2019 to 2022Enrolled750ConditionsSurgical Menopause, BRCA1 Mutation, BRCA2 Mutation, Cardiovascular DiseasesArmsCAC-score
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Maarten J BeekmanDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lara TerraDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Anniek StuursmaDepartment of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Bernadette A M Heemskerk-GerritsenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Jeanine E Roeters van LennepDepartment of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Marc van BeurdenDepartment of Gynaecological Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lena C van DoornDepartment for Gynaecologic Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Joanne A de HulluDepartment for Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
Eleonora B L van DorstDepartment of Gynaecologic Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Constantijne H MomDepartment of Gynaecological Oncology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Brigitte F M SlangenDepartment of Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, The Netherlands.
Christina MiteaDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Riemer H J A SlartDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
Miranda M SnoerenDepartment of Radiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Marcel P StokkelDepartment of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hein J VerberneDepartment of Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Bart de KeizerDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Catharina M KorseDepartment of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Katja N GaarenstroomDepartment of Gynaecology, Leiden University Medical Center, Leiden, The Netherlands.
Klaartje van EngelenDepartment of Human Genetics, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Lizet E van der KolkFamily Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
J Margriet ColléeDepartment of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Marijke R WeversDepartment of Clinical Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Margreet G E M AusemsDepartment of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Lieke P V BergerDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Encarna B Gomez GarciaDepartment of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
Christi J van AsperenDepartment for Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Maartje J HooningDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Angela H E M MaasDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Marian J E MouritsDepartment of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Flora E van Leeuwen *Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
M Carola Zillikens *Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands. m.c.zillikens@erasmusmc.nl.ORCID http://orcid.org/0000-0001-9186-3423

Funding

KWF Kankerbestrijding NCT03835793
6 · The paper itself

Abstract

Women at high familial risk for ovarian cancer are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO), leading to surgical menopause and short-term bone loss. However, long-term studies and osteoporosis screening recommendations are lacking. Eighteen years after premenopausal RRSO, women had lower bone mineral density compared with women who underwent a postmenopausal RRSO. PURPOSE: To prevent ovarian cancer, BRCA1/2 germline pathogenic variant carriers are recommended to undergo premenopausal risk-reducing salpingo-oophorectomy (RRSO). Premenopausal RRSO leads to immediate menopause, which has been associated with an acute phase of rapid bone loss. However, data on long-term bone mineral density (BMD) is scarce and inconclusive. We aimed to investigate long-term BMD after premenopausal RRSO.

methodsWe conducted a cross-sectional study nested in a nationwide cohort of women at high familial risk of ovarian cancer. We compared 493 women who underwent premenopausal RRSO (≤ 45 years) with 228 women who underwent postmenopausal RRSO (≥ 54 years). BMD was assessed by Dual-Energy X-ray absorptiometry of the lumbar spine (LS) and femoral neck (FN). Age differences between the pre- and postmenopausal RRSO groups were accounted for using Z-scores.

resultsMedian age at study visit was 59.2 years in the premenopausal RRSO group and 69.7 years in the postmenopausal RRSO group (P < 0.001), median time since premenopausal RRSO was 18.1 years (IQR 15.3-21.3). In multivariable regression analyses the BMD Z-scores of the LS and FN were significantly lower for the premenopausal compared with the postmenopausal RRSO group (β -0.88, 95% CI, -1.10,-0.66 for LS; β -0.51, 95% CI, -0.71,-0.31 for FN). Relative risks (RRs) of having a Z-score ≤ -1.0 were also higher in the premenopausal compared with the postmenopausal RRSO group (RR 2.35, 95% CI, 1.26-4.40 and RR 1.84, 95% CI, 1.08-3.13, respectively).

conclusionPremenopausal RRSO appears to be associated with long-term lowering of BMD Z-scores, emphasizing the importance of counseling women about bone health after premenopausal RRSO. CLINICAL

trial registrationThe pre-registered clinical trial number is < NCT03835793 > .

Indexed as

Bone DensitySalpingo-oophorectomyAbsorptiometry, PhotonAdultAgedCross-Sectional StudiesFemaleFemur NeckHumansLumbar VertebraeMiddle AgedOsteoporosisOsteoporosis, PostmenopausalOvarian NeoplasmsPostmenopausePremenopauseBone Mineral DensityDXAEarly MenopauseEpidemiologyEstrogen

Identifiers

PMID41045325
PMCPMC12628374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.